Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CCR1 | P32246 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | CCR8 | P51685 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38650638 | 1.00 | KDM4E (0.50) | KDM4ELMNACYP1A2CCR1CCR5 | |
| Hydrochloric Acid SCHEMBL7056332 | 0.98 | CYP1A2 (0.49) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL5570130 | 0.98 | CYP1A2 (0.49) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL28850621 | 0.91 | MEN1 (0.48) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL9848049 | 0.88 | KDM4E (0.60) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL27521956 | 0.85 | TDP1 (0.48) | KDM4ELMNACYP1A2CCR1CCR5 | |
| Oxazole SCHEMBL11314215 | 0.84 | CYP1A2 (0.39) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL7052857 | 0.83 | TSHR (0.44) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL4812728 | 0.83 | CCR1 (0.50) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL30989133 | 0.82 | KDM4E (0.72) | KDM4ELMNACYP1A2CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0979820-B1 | 2-Phenylpyridine derivatives and production method thereof | SUMIKA FINE CHEMICALS CO LTD (JP) | 2003-05-07 | — | — | EP | claimed |
| US-6268503-B1 | REACTING 2-(4-BROMOMETHYLPHENYL)PYRIDINE SALT OR 2-(4-DIBROMOMETHYLPHENYL)PYRIDINE WITH HEXAMETHYLENETETRAMINE AND WATER TO PROVIDE 4-(PYRIDIN-2-YL)BENZALDEHYDE | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2001-07-31 | — | — | US | claimed |
| US-6147218-A | 2-phenylpyridine derivative and production method thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2000-11-14 | — | — | US | claimed |
| EP-0979820-A1 | 2-Phenylpyridine derivatives and production method thereof | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2000-02-16 | — | — | EP | claimed |
| EP-3725789-B1 | 7,8-DIHYDRO-[2H]-IMIDAZO-[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PHOSPHODIESTERASE 1 (PDE1) INHIBITORS FOR TREATING DISEASES, DISORDERS OR INJURIES OF THE CENTRAL NERVOUS SYSTEM (CNS) | INTRA CELLULAR THERAPIES INC (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-107106563-B | Compounds and methods | 细胞内治疗公司 | 2021-05-25 | — | — | CN | disclosed |
| EP-3193878-B1 | 7,8-DIHYDRO-[2H]-IMIDAZO-[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PHOSPHODIESTERASE 1 (PDE1) INHIBITORS FOR TREATING DISEASES, DISORDERS OR INJURIES OF THE CENTRAL NERVOUS SYSTEM (CNS) | INTRA CELLULAR THERAPIES INC (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3725789-A1 | 7,8-DIHYDRO-[2H]-IMIDAZO-[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PHOSPHODIESTERASE 1 (PDE1) INHIBITORS FOR TREATING DISEASES, DISORDERS OR INJURIES OF THE CENTRAL NERVOUS SYSTEM (CNS) | Intra-Cellular Therapies, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3091983-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A PDE-1 INHIBITOR AND A PDE-2 INHIBITOR | INTRA CELLULAR THERAPIES INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190144460-A1 | COMPOUNDS AND METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10150774-B2 | Compounds and methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-9938284-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996033170-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | NOVARITS AG (CH) | 1996-10-24 | — | — | WO | disclosed |
| EP-0728145-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | Ciba-Geigy Japan Limited (JP) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
| EP-0665223-A1 | Antitumor agent, novel 3(2H)-pyridazinone derivatives and their preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-08-02 | — | — | EP | disclosed |
| WO-1995012611-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | JAPAT LTD. (CH) | 1995-05-11 | — | — | WO | disclosed |
| US-4859670-A | 2-Azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof, agents containing same, and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-22 | — | — | US | disclosed |
| EP-0237962-A2 | 2-Azolylmethyl-2-aryl-1,3-dioxolanes and their preparation, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10150774-B2 | Compounds and methods | BDNF, PYGB, SMPD1 | KDM4E 3320/4885LMNA 1645/4885CYP1A2 2963/4885 |
| US-20190144460-A1 | COMPOUNDS AND METHODS | BDNF, PYGB, SMPD1 | KDM4E 3320/4885LMNA 1645/4885CYP1A2 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.